Source: Empower Clinics Inc.
  • Empower Clinics (CBDT) has announced that it will close two The Medi-Collective (TMC) clinics in Hamilton and Mississauga
  • Both clinics will no longer operate under TMC as of September 1, 2022
  • Six Ontario clinics will continue to operate
  • Empower is a wellness healthcare company that provides patients clinics with digital, telemedicine care, and medical diagnostics laboratories
  • Empower Clinics Inc. (CBDT) opened trading at C$0.05

Empower Clinics (CBDT) has announced that it will close two The Medi-Collective (TMC) clinics in Hamilton and Mississauga.

Both clinics will no longer operate under TMC as of September 1, 2022.

“After analyzing the operations of our TMC clinics and taking into consideration the potential for future growth, we’ve decided that both Hamilton and Mississauga clinics do not fully meet our expansion goals”, stated Steven McAuley, Chairman and CEO of Empower Clinics.

“These decisions are not made lightly but we need to adjust to our current climate and invest our resources where patients can experience truly integrated health care.”

Carolyn Shields, Senior Vice President of Operations for TMC, added,

“These two locations are the smallest of our clinics and don’t have the optimal ability to add wellness or private services. In the current healthcare landscape with a severe shortage of physicians, TMC needs to focus on clinics that maximize revenue opportunities by offering integrated health care with both traditional medical and wellness solutions.”

Empower is a wellness healthcare company that provides patients clinics with digital, telemedicine care and medical diagnostics laboratories.

Empower Clinics Inc. (CBDT) opened trading at C$0.05.


More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

Theratechnologies phases down preclinical oncology research

Biopharmaceutical company Theratechnologies (TSX:TH) announced it will phase down its preclinical oncology research activities.